Notes on verification

Verbatim claim traces to epicentro.iss.it (Italian public health institute), which itself derives from the AGCM 2014 antitrust ruling against Roche/Novartis. Multiple independent sources (AGCM ruling, TAR Lazio review, parliamentary Q&A, academic commentary) corroborate the same order of magnitude (15-80 euro), though exact framing (per injection vs per cycle) varies slightly across sources. [tier=bronze indep_score=0.525 clusters=3 claim_tier=notable | framework convergence=partial on AGCM Antitrust ruling n. 24823 (27 February 2014) on Roche/Novartis Avastin-Lucentis case (upstreams: Autorità Garante della Concorrenza e del Mercato (AGCM) ruling n. 24823/2014, TAR Lazio administrative court ruling) — publishers independent, evidence may not be | kind=attributed eligibility=high (extractor: attributed/medium)]